» Articles » PMID: 10379787

Review Article: the Role of Tumor Necrosis Factor in Renal Ischemia-reperfusion Injury

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 1999 Jun 24
PMID 10379787
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Renal ischemia-reperfusion injury induces a cascade of events leading to cellular damage and organ dysfunction. Tumor necrosis factor-alpha (TNF), a potent proinflammatory cytokine, is released from the kidney in response to, and has been implicated in the pathogenesis of, renal ischemia-reperfusion injury. TNF induces glomerular fibrin deposition, cellular infiltration and vasoconstriction, leading to a reduction in glomerular filtration rate (GFR). The signaling cascade through which renal ischemia-reperfusion induces TNF production is beginning to be elucidated. Oxidants released following reperfusion activate p38 mitogen activated protein kinase (p38 MAP kinase) and the TNF transcription factor, NFkappaB, leading to subsequent TNF synthesis. In a positive feedback, proinflammatory fashion, binding of TNF to specific TNF membrane receptors can reactivate NFkappaB. This provides a mechanism by which TNF can upregulate its own expression as well as facilitate the expression of other genes pivotal to the inflammatory response. TNF receptor binding can also induce renal cell apoptosis, the major form of cell death associated with renal ischemia-reperfusion injury. Anti-TNF strategies targeting p38 MAP kinase, NFkappaB, and TNF itself are being investigated as methods of attenuating renal ischemic injury. The control of TNF production and activity represents a realistic goal for clinical medicine.

Citing Articles

Activation of Purinergic P2Y2 Receptor Protects the Kidney Against Renal Ischemia and Reperfusion Injury in Mice.

Jeong K, Je J, Dusabimana T, Karekezi J, Nugroho T, Ndahigwa E Int J Mol Sci. 2024; 25(23).

PMID: 39684275 PMC: 11641314. DOI: 10.3390/ijms252312563.


Comprehensive Overview of Innovative Strategies in Preventing Renal Ischemia-reperfusion Injury: Insights from Bibliometric and Analyses.

Rysmakhanov M, Zare A, Smagulov A, Abenova N, Mussin N, Sultangereyev Y Curr Pharm Des. 2024; 30(20):1578-1598.

PMID: 38676525 DOI: 10.2174/0113816128283420240409050754.


Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF-α, NF-κB, and Bax.

Abd-Eldayem A, Makram S, Messiha B, Abd-Elhafeez H, Abdel-Reheim M Sci Rep. 2024; 14(1):7434.

PMID: 38548778 PMC: 10978894. DOI: 10.1038/s41598-024-57300-x.


The role of non-protein-coding RNAs in ischemic acute kidney injury.

Sabet Sarvestani F, Afshari A, Azarpira N Front Immunol. 2024; 15:1230742.

PMID: 38390339 PMC: 10881863. DOI: 10.3389/fimmu.2024.1230742.


Pharmacological functions of salidroside in renal diseases: facts and perspectives.

Liu Q, Chen J, Zeng A, Song L Front Pharmacol. 2024; 14:1309598.

PMID: 38259279 PMC: 10800390. DOI: 10.3389/fphar.2023.1309598.